NMIBC

19 registered clinical trials studyying NMIBC — 13 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patien NCT07445308	Shenyang Sunshine Pharmaceutical Co., LTD.	Phase 1 / Phase 2
Not Yet Recruiting	A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects Wi NCT07424287	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 3
Not Yet Recruiting	DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC NCT07207824	Fudan University	Phase 3
Recruiting	ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive NCT06800963	ImmunityBio, Inc.	Phase 1 / Phase 2
Not Yet Recruiting	Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial NCT06982690	National Taiwan University Hospital	N/A
Not Yet Recruiting	A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. NCT07064863	Queen's University	Phase 1 / Phase 2
Recruiting	A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer NCT06735287	The First Affiliated Hospital with Nanjing Medical University	N/A
Not Yet Recruiting	A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TU NCT06630871	Fujian Medical University Union Hospital	Phase 2
Not Yet Recruiting	SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resec NCT06588179	Fudan University	Phase 1 / Phase 2
Recruiting	Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer NCT06889623	Changhai Hospital	N/A
Recruiting	A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of NCT06991868	Peking University First Hospital	—
Active Not Recruiting	A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer NCT06181266	Prokarium Ltd	Phase 1
Recruiting	RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects NCT05943379	RemeGen Co., Ltd.	Phase 2
Recruiting	A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer NCT05483868	Aura Biosciences	Phase 1
Completed	A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIB NCT05375903	UroGen Pharma Ltd.	Phase 1
Terminated	A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer ( NCT05014139	Astellas Pharma Global Development, Inc.	Phase 1
Completed	A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscl NCT07505615	Ding-Wei Ye	Phase 1 / Phase 2
Completed	A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk NCT03914794	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2
Available	ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Can NCT06810141	ImmunityBio, Inc.	—